DigestRedComo funciona
Red
/
Empresas
Ge
No verificado

Genmab A/S

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

22 Comunicados de prensa

Ver todos los comunicados de prensa
18/11/2025
Higiene alimentaria
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Industria
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
03/11/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Industria
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
29/09/2025
Biotecnología
Salud
Oncología
Medicina - Varios
Mercado de valores
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
03/09/2025
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Eventos
Industria
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
26/08/2025
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
02/06/2025
Biotecnología
Sanidad
Salud
Medicina - Varios
Oncología
Eventos
Industria
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
22/05/2025
Eventos
Ferias y Congresos
Industria
Biología
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Higiene alimentaria
Medicina - Varios
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
14/05/2025
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
02/05/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
31/03/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Fuente
Genmab A/S
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0